|1.||Nair, Parameswaran: 3 articles (04/2015 - 11/2011)|
|2.||Walsh, Garry M: 3 articles (01/2013 - 06/2009)|
|3.||Bachert, Claus: 2 articles (12/2015 - 11/2006)|
|4.||Castro, Mario: 2 articles (05/2015 - 11/2011)|
|5.||Young, James: 2 articles (02/2012 - 11/2011)|
|6.||Henkel, Timothy: 2 articles (02/2012 - 11/2011)|
|7.||Wilkins, H Jeffrey: 2 articles (02/2012 - 11/2011)|
|8.||Zhang, Luo: 1 article (12/2015)|
|9.||Gevaert, Phillippe: 1 article (12/2015)|
|10.||Pavord, Ian D: 1 article (08/2015)|
|1.||Asthma (Bronchial Asthma)
05/01/2015 - "In both studies, patients receiving reslizumab had a significant reduction in the frequency of asthma exacerbations (study 1: rate ratio [RR] 0·50 [95% CI 0·37-0·67]; study 2: 0·41 [0·28-0·59]; both p<0·0001) compared with those receiving placebo. "
11/15/2011 - "Patients receiving reslizumab showed significantly greater reductions in sputum eosinophils, improvements in airway function, and a trend toward greater asthma control than those receiving placebo. "
05/01/2015 - "Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials."
04/01/2015 - "Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials."
11/15/2011 - "Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study."
04/01/2015 - "Rebound eosinophilia after cessation of reslizumab and attenuation of the treatment response with repeated dosing had been reported. "
08/01/2015 - "Recognition of the link between airway or blood eosinophilia and treatment response was also important in the clinical testing of the alternative IL-5 blocker, such as reslizumab, which is currently being evaluated in a phase III randomized controlled trial (RCT) after having shown to improve lung function, improve symptom score and reduce sputum eosinophilia in a smaller phase IIb study. "
01/01/2015 - "Early trials of monoclonal antibodies targeting the biological activity of IL-5, including reslizumab, mepolizumab, and benralizumab, were performed on asthmatics with no concern for evidence of eosinophilia. "
05/01/2015 - "Monoclonal antibodies directed towards interleukin-5, such as mepolizumab or reslizumab, were shown to be very effective at reducing blood and airways eosinophilia. "
01/01/2014 - "Examples include the efficacy of omalizumab in patients with severe refractory atopic asthma characterized by raised serum total IgE, mepolizumab, reslizumab, and benralizumab in patients with recurrent eosinophilic exacerbations characterized by blood and sputum eosinophilia despite high doses of corticosteroids, and lebrikizumab, pitrakinra, dupilumab, and tralokinumab that target the IL-4/IL-13 signalling pathways in patients with eosinophilic asthma or raised serum periostin. "
|3.||Nasal Polyps (Nasal Polyp)
11/01/2006 - "In a double-blind, placebo-controlled, randomized, 2-center safety and pharmacokinetic study, 24 subjects with bilateral nasal polyps were randomized to receive a single intravenous infusion of reslizumab, a humanized anti-human IL-5 mAb, at 3 mg/kg or 1 mg/kg or placebo. "
12/01/2015 - "As a consequence, several innovative approaches targeting the TH2 bias with humanized mAbs have been subjected to proof-of-concept studies in patients with CRS with nasal polyps with or without comorbid asthma: omalizumab, reslizumab, mepolizumab, and recently dupilumab. "
02/01/2012 - "Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial."
02/01/2012 - "Reslizumab significantly reduced intraepithelial esophageal eosinophil counts in children and adolescents with eosinophilic esophagitis. "
07/01/2010 - "This article considers the current status of the clinical development of reslizumab for pediatric eosinophilic esophagitis."
07/01/2010 - "Reslizumab for pediatric eosinophilic esophagitis."
02/01/2012 - "We sought to evaluate the effect of reslizumab, a neutralizing antibody against IL-5, in children and adolescents with eosinophilic esophagitis. "
|5.||Hypereosinophilic Syndrome (Loeffler Endocarditis)
08/01/2010 - "Literature search methodology utilized www.pubmed.gov and www.clinicaltrials.gov with search terms including hypereosinophilic syndrome and corticosteroid side-effects coupled with search terms including eosinophils, mepolizumab and reslizumab through March 2010. "
06/01/2009 - "Clinical trials for reslizumab have been completed in a small number of patients with asthma, nasal polyposis, hypereosinophilic syndrome (HES) and eosinophil gastroenteritis (EG). "
|1.||Interleukin-5 (Interleukin 5)
|6.||Immunoglobulin E (IgE)
|7.||Adrenal Cortex Hormones (Corticosteroids)